[ad_1]
The European Union approved emergency use of the Johnson & Johnson vaccine today, Thursday.
Earlier today, the European Medicines Agency announced that it would consider licensing the Johnson & Johnson vaccine.
These developments come at a time when European sources announced the day before yesterday that Johnson & Johnson is facing a supply problem with vaccine components, noting that the company refuses to comment on a possible delay in the supply of vaccines.
For its part, Johnson & Johnson have confirmed that the European Union will start receiving shipments of the vaccine in the second quarter of this year.
Since Johnson & Johnson revealed its vaccine and its effectiveness, estimated to be less than 72% compared to around 95% for Moderna and Pfizer Point, health officials in the United States were concerned that some Americans would see the new vaccine as a lesser choice. . than others, but the first days Whoever proposed it showed something surprising and unexpected.
In a single dose
Many people have expressed their eagerness to obtain it; Because they want one-dose relief, The New York Times reported last week.
Public health officials have also shown enthusiasm for how quickly they can dispense a single dose, especially in remote communities who may not be able to easily access the vaccine.
In addition, this vaccine has many other benefits. Dr. Joseph Kanter, head of health in Louisiana, explained that a single dose would allow his condition to reduce the costs of personnel and operations related to the second dose.
It can also be given to people who may have difficulty reaching a second dose, such as those who are homeless or about to be released from prison, as several Oregon health officials explained. , or groups of mobile farming communities with three working seasons. Or four weeks.
Source link
